Nexium packs 10mg №28
-
All payments are encrypted via SSL
-
Full Refund if you haven't received your order
Enteric-coated pellets and granules
Composition
1 pack Contains esomeprazole sodium 10 mg.
Packing
28 pcs.
Mechanism of action
H inhibitor+-TO+-ATP-ase. The active substance of the drug Nexium - esomeprazole, S-isomer of Omeprazole, reduces the secretion of hydrochloric acid in the stomach by specific inhibition of the acid pump in the parietal cells. S- and R-isomer of omeprazole have similar pharmacodynamic activity.
Esomeprazole is a weak base and is activated in the acidic environment of the secretory tubules of the parietal cells of the gastric mucosa, where it inhibits the activity of H+-K+-ATP-ase and thereby blocks the final stage of the secretion of hydrochloric acid. Nexium inhibits both basal and stimulated gastric secretion.
The effect of the drug develops within 1 hour after it is taken orally at a dose of 20 mg or 40 mg. When taking the drug daily for 5 days at 20 mg 1 time / day, the average maximum concentration of acid in the gastric contents after stimulation with pentagastrin is reduced by 90% (when measuring the concentration of acid 6-7 hours after taking the dose on the 5th day of therapy).
In patients with symptoms of gastroesophageal reflux disease, after 5 days of daily administration of Nexium orally at a dose of 20 mg or 40 mg of pH in the stomach with daily monitoring was higher than 4 for an average of 13 and 17 h, respectively.Among patients who took 20 mg of the drug per day, the maintenance of acidity at a pH above 4 for 8, 12 and 16 hours was achieved in 76%, 54% and 24%, respectively. For 40 mg of esomeprazole, this ratio was 97%, 92% and 56%, respectively.
Analysis of the pharmacokinetic data revealed a relationship between acid secretion and plasma concentration of the drug (the AUC parameter was used to estimate the concentration).
When receiving 40 mg of the drug per day, cure of reflux esophagitis occurs in 78% of patients after 4 weeks of therapy and in 93% of patients after 8 weeks of therapy.
Treatment with Nexium at a dose of 20 mg 2 times / day in combination with appropriate antibiotics for one week leads to successful eradication of Helicobacter pylori in approximately 90% of patients.
Patients with uncomplicated duodenal ulcer after a week-long course of eradication therapy do not require further treatment with antisecretory drugs for healing the ulcer.
During the use of the drug, the level of gastrin in the plasma increases as a result of reduced intragastric acid secretion.
In patients who have used antisecretory drugs for a long time, the formation of glandular cysts in the stomach is more often observed. This phenomenon is due to physiological changes as a result of inhibition of acid secretion. The cysts are benign and tend to disappear.
Gastroesophageal Reflux Disease:
- treatment of erosive reflux esophagitis;
- long-term maintenance therapy to prevent recurrence in patients with cured esophagitis;
- symptomatic therapy of gastroesophageal reflux disease.
Eradication of Helicobacter pylori (in combination with antibiotic therapy), as well as:
- treatment of duodenal ulcer associated with Helicobacter pylori;
- prevention of recurrence of peptic ulcers associated with Helicobacter pylori. Gastroesophageal Reflux Disease:
- treatment of erosive reflux esophagitis;
- long-term maintenance therapy to prevent recurrence in patients with cured esophagitis;
- symptomatic therapy of gastroesophageal reflux disease.
Eradication of Helicobacter pylori (in combination with antibiotic therapy), as well as:
- treatment of duodenal ulcer associated with Helicobacter pylori;
- prevention of recurrence of peptic ulcers associated with Helicobacter pylori.
Contraindications
Hypersensitivity to esomeprazole, substituted benzimidazoles or other components of the drug Nexium.
Pregnancy and Breastfeeding
Currently there are no data on the use of Nexium during pregnancy. Drug administration during this period is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
It is currently unknown if esomeprazole is excreted in breast milk, therefore, Nexium should not be administered during breastfeeding.
ATexperimental animal studies no adverse effect of esomeprazole on the development of the embryo or fetus has been identified. The introduction of the racemic drug also did not have any negative impact on the course of pregnancy in animals, childbirth and the period of postnatal development.
Dosage and administration
Fortreatment of erosive reflux esophagitis the drug is prescribed in a single dose of 40 mg 1 time / day for 4 weeks. An additional 4-week course of therapy is recommended in cases where the symptoms of the disease persist after the first course.
Forlong-term maintenance treatment of patients with cured esophagitis to prevent relapse, the drug is prescribed 20 mg 1 time / day.
Forsymptomatic treatment of gastroesophageal reflux disease without esophagitis the drug is prescribed in a dose of 20 mg 1 time / day. If after 4 weeks of treatment the symptoms do not disappear, an additional examination of the patient should be carried out. After elimination of symptoms, it is possible to switch to the mode of taking the drug "if necessary", i.e. take Nexium at 20 mg 1 time / day if symptoms occur before they are removed.
Foreradication of Helicobacter pylori, for the treatment of duodenal ulcers associated with Helicobacter pylori, to prevent the recurrence of peptic ulcers associated with Helicobacter pylori, Nexium is prescribed in a single dose of 20 mg, Amoxicillin - 1 g, Clarithromycin - 500 mg. All drugs are taken 2 times / day for 7 days.
In the appointment of the drug to patients with impaired renal function dose adjustment is not required.The drug is used with caution in patients with severe renal failure due to the limited clinical experience of its use in this category of patients.
When Nexium is prescribed to patients with mild or moderately impaired liver function, dose adjustment is not required. Patients with severely impaired liver function dose should not exceed 20 mg / day.
Elderly people do not need to adjust the dosage regimen.
Adverse reactions
With the use of esomeprazole, rarely encountered side effects of the racemic drug (omeprazole) can be expected. In conducting clinical trials of esomeprazole, such effects have not been described.
When conducting clinical trials, the following side effects were identified:
Gastrointestinal: often (> 0.01, but <0.1) - abdominal pain, diarrhea, nausea, vomiting, constipation; rarely (> 0.001, but <0.01) - dry mouth.
From the side of the central nervous system: often (> 0.01, but <0.1) - headache; rarely (> 0.001, but <0.01) - dizziness.
Dermatologic: rarely (> 0.001, but <0.01) - dermatitis, pruritus, urticaria.
None of these effects depended on the dose of the drug.
The following side effects were observed with the use of the racemic drug (omeprazole) and can also be expected with the use of esomeprazole.
Nervous system: paresthesia, drowsiness, insomnia, dizziness, reversible confusion, anxiety, agitation, depression, hallucinations (mainly in seriously ill patients).
On the part of the endocrine system: gynecomastia.
Gastrointestinal: stomatitis, gastrointestinal candidiasis; increased activity of liver enzymes, encephalopathy in patients with prolonged severe liver diseases, hepatitis with (or without) jaundice, liver failure.
Hemic and lymphatic: leukopenia, thrombocytopenia, agranulocytosis and pancytopenia.
From the musculoskeletal system: joint pain, muscle weakness and myalgia.
Dermatologic: sypyp, photosensitization, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, alopecia.
Allergic reactions: angioedema, fever, bronchospasm, interstitial nephritis and anaphylactic shock.
Other: general weakness, increased sweating, peripheral edema, blurred vision, changes in taste and hyponatremia.
Before the prescription of esomeprazole, the possibility of a malignant neoplasm should be excluded, since treatment with Nexium can lead to a smoothing of symptoms and delay the diagnosis.
Patients taking the drug for a long period (especially more than a year) should be under the regular supervision of a physician.
Patients who are on “on-demand therapy” should be instructed to contact their physician when symptoms change. Taking into account fluctuations in the concentration of esomeprazole in plasma in the appointment of the drug in the mode of "therapy on demand," you should consider the interaction of the drug with other drugs.
In appointing Nexium for the eradication of Helicobacter pylori, the possibility of drug interaction for all components of triple therapy should be taken into account. Clarithromycin is a potent inhibitor of CYP3A4, therefore, all contraindications and interactions of clarithromycin should be considered when used in patients taking other drugs that are metabolized with CYP3A4 (for example, cisapride).
Patients with hereditary fructose intolerance, glucose – galactose malabsorption, or sucrose – isomalta deficiency should not take this drug.
Use in pediatrics
The use of the drug in children is not recommended due to lack of data.
Influence on ability to drive motor transport and control mechanisms
No effect of the drug on the ability to drive vehicles and control mechanisms.
Effect of esomeprazole on the pharmacokinetics of other drugs
When using Nexium simultaneously with other drugs, the mechanism of absorption of which depends on the acidity of the medium, it is possible to decrease or increase the absorption of other drugs. As with other drugs that suppress the secretion of acid or antacid agents, treatment with esomeprazole may lead to a decrease in the absorption of Ketoconazole or itraconazole.
The combined use of Nexium with drugs,in the metabolism of which CYP2C19 is involved, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, can lead to an increase in plasma concentrations of these drugs and require a reduction in their doses.
With the joint intake of 30 mg of Nexium and diazepam, the clearance of the enzyme-substrate complex (CYP2C19-diazepam) decreases by 45%.
With the simultaneous use of Nexium at a dose of 40 mg, residual concentrations of phenytoin in the blood plasma of patients with epilepsy increase by 13% (it is recommended to control the concentration of phenytoin in the blood plasma when prescribing esomeprazole and when it is canceled).
In healthy volunteers, co-administration of cisapride with 40 mg of Nexium resulted in a 32% increase in the AUC of cisapride and an increase in T1/2 cisapride by 31%, however, plasma cisapride concentrations did not change significantly. The slight lengthening of the QT interval, which was observed with cisapride monotherapy, did not increase with the addition of Nexium.
With the simultaneous use of Nexium does not cause clinically significant changes in the pharmacokinetic parameters of amoxicillin, quinidine and Warfarin .
The effect of drugs on the pharmacokinetics of esomeprazole.
With the simultaneous use of Nexium with clarithromycin (500 mg 2 times / day), AUC of esomeprazole increases by 2 times (dose adjustment of Nexium is not required).
Currently not described cases of overdose. Single dose of 80 mg of esomeprazole did not cause any negative effects.
Treatment: Symptomatic and supportive therapy is performed if necessary. The specific antidote is unknown. Dialysis is ineffective, because esomeprazole binds to plasma proteins .
The preparation should be stored in the places inaccessible for children, at a temperature below 30 ° C.
Nexium packages